Royce & Associates LP Has $4.72 Million Stock Holdings in LifeMD, Inc. (NASDAQ:LFMD)

Royce & Associates LP lifted its holdings in shares of LifeMD, Inc. (NASDAQ:LFMD) by 14.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 901,041 shares of the company’s stock after acquiring an additional 114,710 shares during the period. Royce & Associates LP owned approximately 2.09% of LifeMD worth $4,721,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in LFMD. Vanguard Group Inc. lifted its stake in LifeMD by 12.5% during the 1st quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company’s stock valued at $11,875,000 after acquiring an additional 128,701 shares in the last quarter. Los Angeles Capital Management LLC raised its holdings in shares of LifeMD by 852.6% in the third quarter. Los Angeles Capital Management LLC now owns 121,585 shares of the company’s stock valued at $637,000 after purchasing an additional 108,822 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of LifeMD by 63.6% during the second quarter. Bank of New York Mellon Corp now owns 234,583 shares of the company’s stock valued at $1,609,000 after purchasing an additional 91,183 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in LifeMD by 261.8% during the first quarter. Acadian Asset Management LLC now owns 116,655 shares of the company’s stock worth $1,198,000 after purchasing an additional 84,413 shares during the last quarter. Finally, X Square Capital LLC bought a new stake in LifeMD in the 2nd quarter worth about $509,000. Institutional investors and hedge funds own 35.52% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on LFMD. B. Riley initiated coverage on LifeMD in a research note on Friday, August 23rd. They issued a “buy” rating and a $11.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $15.00 price objective on shares of LifeMD in a research note on Friday, September 20th. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of LifeMD in a research note on Monday, November 11th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $12.00.

LifeMD Stock Performance

NASDAQ:LFMD opened at $5.26 on Tuesday. LifeMD, Inc. has a 1 year low of $3.99 and a 1 year high of $12.88. The company has a debt-to-equity ratio of 10.83, a current ratio of 0.83 and a quick ratio of 0.78. The business has a fifty day simple moving average of $4.99 and a two-hundred day simple moving average of $6.29. The company has a market capitalization of $227.81 million, a P/E ratio of -8.22 and a beta of 1.23.

LifeMD Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.